Aquaculture Bacterial Treatment Market By Treatment Type (Antibiotics, Probiotics, Bacterial Vaccines, Bacteriophage Therapy, Immunostimulants); By Bacterial Disease (Vibriosis, Aeromonas Infections, Streptococcosis, Columnaris Disease, Edwardsiellosis); By Species (Finfish, Crustaceans, Mollusks); By Route of Administration (Oral Administration, Injectable Administration, Immersion Administration, Water-Based Administration); By Application (Disease Treatment, Disease Prevention, Bacterial Infection Control); By End User (Commercial Fish Farms, Shrimp Farms, Hatcheries, Nurseries); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Disease Prevention and Therapeutic Advancements Shaping the Aquaculture Bacterial Treatment Market?

The Global Aquaculture Bacterial Treatment Market was estimated at USD 1.65 billion in 2025 and is projected to reach USD 2.74 billion by 2032, registering a CAGR of 7.56% during 2026–2032, according to Strategic Market Research. Aquaculture bacterial treatment involves the use of antibiotics, vaccines, and other antibacterial therapies to prevent and control bacterial infections in farmed fish and shrimp

 

Bacterial infections can cause substantial losses in shrimp farming. The World Organisation for Animal Health (WOAH) reports that AHPND can cause mortality rates of up to 100% in severely affected shrimp populations, often within 30–35 days of stocking. WOAH's 2025 antimicrobial-use report also documented antibiotic and other antimicrobial use in aquatic animal farming, confirming the continued role of medicines in managing infectious diseases. These infections create a need for effective treatments, particularly in intensive fish and shrimp farming operations.

 

In the United States, FDA approved PAQFLOR, a generic florfenicol treatment, in November 2024 for controlling deaths caused by certain bacterial infections in freshwater-reared fish. The approved uses cover diseases such as furunculosis, columnaris, enteric septicemia, and streptococcal septicemia. Preventive treatments are also available, with PHARMAQ offering vaccines against bacterial infections such as vibriosis and furunculosis. These products help farmers manage disease risks through both medication and vaccination.

 

Overall, the aquaculture bacterial treatment market is progressing toward integrated disease management, where preventive vaccination, targeted antimicrobial therapy, and microbiome-supporting technologies are becoming increasingly important for reducing production losses, improving aquatic animal survival, and maintaining profitable aquaculture operations.

 

Which Segments Are Leading the Aquaculture Bacterial Treatment Market, and Where Are the Fastest-Growing Opportunities Emerging?

By Treatment Type: Antibiotic Leadership and Pathogen-Specific Phage Therapies

Leading Segment – Antibiotics

Antibiotics represented the largest share of the Aquaculture Bacterial Treatment Market at approximately 38% in 2025, valued at USD 627 million, and are projected to expand at a CAGR of 4.75% during 2026–2032. Antibiotics are widely used in fish and shellfish farming to treat and control bacterial infections, reduce disease-related mortality, and protect aquaculture production. Their extensive use in intensive farming operations supports their market leadership, while concerns over antimicrobial resistance and environmental contamination are encouraging stricter treatment practices and responsible antibiotic administration.

Fastest-Growing Segment – Bacteriophage Therapy

Bacteriophage therapy accounted for an estimated 6% share of the global Aquaculture Bacterial Treatment Market, valued at USD 99 million in 2025, and is projected to record the fastest CAGR of 15.45% during 2026–2032. The treatment uses specialized viruses known as lytic bacteriophages to selectively infect and destroy disease-causing bacteria in farmed fish and shrimp. Its targeted action helps preserve beneficial microbial communities while reducing reliance on conventional antibiotics, creating commercial opportunities for sustainable bacterial disease management across aquaculture operations.

 

By Bacterial Disease: Vibriosis Control and Streptococcal Vaccination

Leading Segment – Vibriosis

Vibriosis is among the most economically damaging bacterial diseases affecting marine and brackish-water aquaculture, caused by Gram-negative bacteria of the genus Vibrio. In the Aquaculture Bacterial Treatment Market, vibriosis accounted for the largest estimated share of 31%, valued at USD 512 million in 2025, and is projected to expand at a CAGR of 7.29% during 2026–2032. Frequent outbreaks in shrimp and marine fish farming encourage the adoption of antibiotics, vaccines, probiotics, and preventive bacterial management solutions to reduce mortality and production losses.

Fastest-Growing Segment – Streptococcosis

Streptococcosis accounted for an estimated 20% share of the Global Aquaculture Bacterial Treatment Market, valued at USD 330 million in 2025, and is projected to register the fastest CAGR of 8.69% during 2026–2032. Streptococcosis is a major bacterial disease affecting commercially farmed fish, particularly tilapia and trout, requiring targeted antibiotic treatment, vaccination, and disease management protocols. Recurring infection outbreaks, intensive fish farming practices, and the need to reduce mortality and production losses are supporting increased adoption of preventive and therapeutic interventions across aquaculture operations.

 

By Species: Finfish Health Programs and Shrimp Microbial Management

Leading Segment – Finfish

Finfish dominated the Aquaculture Bacterial Treatment Market with an estimated 63% share, valued at USD 1.040 billion in 2025, and are projected to expand at a CAGR of 7.03% during 2026–2032. Bacterial treatment in finfish aquaculture focuses on controlling infections while strengthening natural disease resistance through innate immunity, beneficial gut microbiota, and probiotic supplementation. Lactic acid bacteria and other beneficial microorganisms help suppress harmful pathogens, supporting fish survival, reducing infection-related losses, and encouraging greater adoption of preventive bacterial management solutions across commercial finfish farming operations.

Fastest-Growing Segment – Crustaceans

Crustaceans, including shrimp, prawns, crabs, and lobsters, accounted for an estimated 33% share of the Aquaculture Bacterial Treatment Market, valued at USD 545 million in 2025, and are projected to expand at the fastest CAGR of 8.53% during 2026–2032. Their reliance on innate immune defenses increases susceptibility to bacterial infections, particularly vibriosis, encouraging aquaculture producers to adopt targeted antibacterial treatments, probiotics, and microbial management solutions. Intensive shrimp farming and recurring bacterial outbreaks further support investment in preventive and therapeutic interventions.

 

By Route of Administration: Medicated Feed and High-Value Fish Vaccination

Leading Segment – Oral Administration

Oral administration accounted for the largest estimated share of 42% in the global Aquaculture Bacterial Treatment Market, representing USD 693 million in 2025, and is projected to expand at a CAGR of 6.91% during 2026–2032. Medicated feed provides a practical, relatively low-stress approach to delivering antibiotics, probiotics, and certain preventive treatments to farmed fish and shrimp. Its widespread adoption reflects the convenience of treating large aquaculture populations, minimizing handling-related stress, and supporting bacterial infection prevention and management across intensive fish and shrimp farming operations.

Fastest-Growing Segment – Injectable Administration

Injectable administration accounted for an estimated 26% share of the Aquaculture Bacterial Treatment Market, valued at USD 429 million in 2025, and is projected to register the fastest CAGR of 8.71% during 2026–2032. Intraperitoneal and intramuscular injections enable controlled delivery of antibacterial therapeutics and vaccines directly into fish tissues, supporting systemic absorption while avoiding digestive barriers and treatment losses in surrounding water. Growing adoption of injectable vaccines and targeted antibiotics in commercial salmon and other high-value fish farming operations is strengthening treatment effectiveness and disease management.

 

By Application: Outbreak Treatment and Preventive Stock Protection

Leading Segment – Disease Treatment

Disease treatment accounted for the largest estimated share of 46%, valued at USD 759 million in 2025, and is projected to expand at a CAGR of 6.38% during 2026–2032 in the Aquaculture Bacterial Treatment Market. Therapeutic interventions primarily address active bacterial infections, reduce fish and shrimp mortality, and limit pathogen transmission across aquaculture facilities. Antibiotic treatments, medicated feeds, and targeted antibacterial therapies remain important components of disease management, particularly in intensive aquaculture operations, where timely treatment combined with preventive biosecurity and water quality management helps protect production volumes and minimize economic losses.

Fastest-Growing Segment – Disease Prevention

Disease prevention accounted for an estimated 35% market share, valued at USD 578 million in 2025, and is projected to record the fastest CAGR of 8.98% during 2026–2032. Preventive aquaculture health management increasingly emphasizes vaccination, probiotics, biosecurity measures, water quality monitoring, and regular pathogen screening to minimize bacterial outbreaks. Fish and shrimp farming operations are shifting from reactive antibiotic treatments toward preventive disease management strategies, supporting healthier aquatic populations, reducing mortality-related financial losses, and improving production efficiency across commercial aquaculture facilities.

 

By End User: Commercial Fish Farm Care and Shrimp Biosecurity

Leading Segment – Commercial Fish Farms

Commercial fish farms accounted for the largest estimated share of 49%, valued at USD 809 million in 2025, and are projected to expand at a CAGR of 6.92% during 2026–2032. Bacterial treatment practices across commercial aquaculture operations combine therapeutic medicines, preventive biosecurity measures, and beneficial microbial solutions to control bacterial infections and maintain fish health. Intensive stocking conditions and recurring bacterial disease outbreaks encourage commercial producers to invest in antibiotics, probiotics, vaccines, and water-quality management solutions to protect fish survival rates and minimize production losses.

Fastest-Growing Segment – Shrimp Farms

Shrimp farms accounted for an estimated 31% share of the global Aquaculture Bacterial Treatment Market, valued at USD 512 million in 2025, and are projected to register the fastest CAGR of 8.52% during 2026–2032. Shrimp producers increasingly use beneficial bacterial treatments to maintain water quality, suppress harmful pathogens, improve pond conditions, and reduce dependence on conventional antibiotics. Growing adoption of probiotic formulations and microbial water treatment solutions is supporting healthier shrimp production, improved survival rates, and more sustainable farming practices across commercial aquaculture operations worldwide.

 

By Geography: Asia-Pacific Fish and Shrimp Production Leads Treatment Adoption

Largest and Fastest-Growing Region – Asia-Pacific

Asia-Pacific dominated the global Aquaculture Bacterial Treatment Market with an estimated 48% share, valued at USD 792 million in 2025, and is projected to register the fastest regional CAGR of 7.98% during 2026–2032. Expanding aquaculture production across China, India, Vietnam, and Indonesia is accelerating the adoption of probiotics, bacteriophages, and other bacterial disease management solutions as alternatives to conventional antibiotics. Increasing concerns over antimicrobial resistance and stricter antibiotic residue standards are encouraging aquaculture producers to invest in preventive bacterial treatments and sustainable disease control practices.

 

Which Companies Are Leading the Aquaculture Bacterial Treatment Market Through Vaccines and Advanced Disease Prevention Technologies?

Zoetis (PHARMAQ) – Fish Vaccines, Automated Vaccination, and Bacterial Disease Prevention

Zoetis, through its subsidiary PHARMAQ, is an established global leader in aquaculture vaccines and fish health technologies. According to PHARMAQ's company disclosures, the business delivered approximately 2 billion fish vaccine doses in 2025, supported by around 420 employees and 39 years of dedicated fish health research and development.

Its portfolio includes injectable and immersion vaccines targeting bacterial diseases affecting salmon, tilapia, and other commercial fish species. PHARMAQ Fishteq provides automated vaccination equipment, while PHARMAQ Analytiq offers molecular diagnostics and disease-monitoring services. These integrated technologies strengthen Zoetis's commercial position in preventive bacterial disease management and support recurring vaccination requirements in intensive aquaculture operations.

MSD Animal Health (Merck Animal Health) – AQUAVAC Vaccines and Streptococcal Infection Prevention

MSD Animal Health is another major participant in aquatic animal health, offering bacterial vaccines, therapeutics, and preventive disease-management technologies. Its AQUAVAC Strep SA vaccine targets Streptococcus agalactiae, while AQUAVAC Strep Si targets Streptococcus iniae, two important bacterial pathogens affecting farmed finfish.

According to MSD's Indonesian product registrations, AQUAVAC Strep SA is available in presentations containing 1,000–20,000 doses, allowing vaccination programs to accommodate different commercial production requirements. The company's broader aquaculture portfolio includes injectable, immersion, and oral vaccine technologies for fish health management. Its established vaccine portfolio supports opportunities in bacterial infection prevention, particularly across intensive tilapia and salmon farming.

Other Important Companies and Their Market Roles:

• Alltech – Supplies AQUA-MOS, a functional feed additive, and AQUA-SET, a probiotic product registered in India in April 2025, supporting preventive health and microbial management in aquaculture.

• Evonik Industries AG – Supplies specialized aquaculture feed ingredients and develops probiotic technologies for animal nutrition, contributing to nutritional approaches associated with microbial balance and reduced dependence on antibiotics. Its Ecobiol product is primarily poultry-focused rather than an established aquaculture bacterial treatment.

 

Analyst Commentary: How Will Vaccines and Biological Treatments Reshape Aquaculture Disease Control?

The aquaculture bacterial treatment market is shifting from reactive antibiotic-based treatment toward preventive disease management through bacterial vaccines, probiotics, immunostimulants, and targeted biological therapies. Significant commercial opportunities are emerging in intensive shrimp farming, salmon vaccination programs, and pathogen-specific treatments for vibriosis and streptococcosis. Rising antimicrobial resistance concerns and the financial impact of bacterial outbreaks are encouraging investment in sustainable alternatives. The strongest long-term opportunities lie in preventive solutions that reduce mortality, improve stock survival, minimize treatment costs, and maintain consistent aquaculture production.

 

Aquaculture Bacterial Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.65 Billion
Revenue Forecast in 2032	USD 2.74 Billion
Overall Growth Rate	CAGR of 7.56% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Bacterial Disease, By Species, By Route of Administration, By Application, By End User, By Geography
By Treatment Type	Antibiotics, Probiotics, Bacterial Vaccines, Bacteriophage Therapy, Immunostimulants
By Bacterial Disease	Vibriosis, Aeromonas Infections, Streptococcosis, Columnaris Disease, Edwardsiellosis
By Species	Finfish, Crustaceans, Mollusks
By Route of Administration	Oral Administration, Injectable Administration, Immersion Administration, Water-Based Administration
By Application	Disease Treatment, Disease Prevention, Bacterial Infection Control
By End User	Commercial Fish Farms, Shrimp Farms, Hatcheries, Nurseries
By Region	Asia-Pacific, Europe, Latin America, North America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising bacterial disease incidence in intensive aquaculture, high mortality associated with diseases such as AHPND and vibriosis, increasing adoption of preventive vaccination, growing use of probiotics and immunostimulants, rising interest in bacteriophage-based therapies, concerns over antimicrobial resistance, stricter antibiotic-residue requirements, expansion of commercial fish and shrimp farming, and increasing investment in integrated aquatic animal health management
Customization Option	Available upon request